Recent Advances in Pyrazole-based Protein Kinase Inhibitors as Emerging Therapeutic Targets

被引:0
|
作者
Cetin, Adnan [1 ]
机构
[1] Van Yuzuncu Yil Univ, Fac Educ, Dept Chem, TR-65080 Van, Turkiye
关键词
Cancer; drug discovery; pharmacology; spectroscopy; pyrazole-based protein kinase inhibitors; therapeutic targets; PATENT CITATIONS; SERINE-PROTEASE; POTENT; AGENTS; EGFR;
D O I
10.2174/0113862073252211231024182817
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background Pyrazole-scaffold protein kinase inhibitors (PKIs) have emerged as promising therapeutic agents for the treatment of various diseases, such as cancer, inflammatory disorders, and neurological diseases. This review article provides an overview of the pharmacological properties of pyrazole-scaffold PKIs, including their mechanism of action, selectivity, potency, and toxicity. The article also summarizes the recent developments in the design and synthesis of pyrazole-scaffold PKIs, highlighting the structural features and modifications that contribute to their pharmacological activity. In addition, the article discusses the preclinical and clinical studies of pyrazole-scaffold PKIs, including their efficacy, safety, and pharmacokinetic properties.Methods A comprehensive search has been conducted on several online patent databases, including the United States Patent and Trademark Office (USPTO), the European Patent Office (EPO), and the World Intellectual Property Organization (WIPO). The search was conducted using pyrazole as the keyword. The search was limited to patents filed between 2015 and 2022. Patents were included if they involved articles in the fields of protein kinase inhibitors, and included literature on some pyrazoles and their pharmacological activities.Results Data were extracted from each included patent on the following variables: patent title, patent number, inventors, assignee, filing date, publication date, patent type, and field of invention. Data were extracted from each patent using a standardized form to ensure consistency and accuracy.Conclusion The design and pharmacological evaluation of organic compounds containing pyrazole structure as biologically active substances have been done, and the key structures from the pharmacological data obtained as protein kinase inhibitors have been addressed in detail. The review concludes with a discussion on the current challenges and future directions for the development of pyrazole-scaffold PKIs as therapeutic agents. Overall, this review article provides a comprehensive summary of the pharmacological properties of pyrazole-scaffold PKIs, which will be of interest to researchers and clinicians in the field of drug discovery and development.
引用
收藏
页码:2791 / 2804
页数:14
相关论文
共 50 条
  • [41] Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors: Part 1
    Lee-Dutra, Alice
    Wiener, Danielle K.
    Arienti, Kristen L.
    Liu, Jing
    Mani, Neelakandha
    Ameriks, Michael K.
    Axe, Frank U.
    Gebauer, Damara
    Desai, Pragnya J.
    Nguyen, Steven
    Randal, Mike
    Thurmond, Robin L.
    Sun, Siquan
    Karlsson, Lars
    Edwards, James P.
    Jones, Todd K.
    Grice, Cheryl A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (07) : 2370 - 2374
  • [42] Pyrazole-Based Acid Ceramidase Inhibitors: Design, Synthesis, and Structure-Activity Relationships
    Diamanti, Eleonora
    Bottegoni, Giovanni
    Goldoni, Luca
    Realini, Natalia
    Pagliuca, Chiara
    Bertozzi, Fabio
    Piomelli, Daniele
    Pizzirani, Daniela
    SYNTHESIS-STUTTGART, 2016, 48 (17): : 2739 - 2756
  • [43] Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elements
    Ameriks, Michael K.
    Axe, Frank U.
    Bembenek, Scott D.
    Edwards, James P.
    Gu, Yin
    Karlsson, Lars
    Randal, Mike
    Sun, Siquan
    Thurmond, Robin L.
    Zhu, Jian
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (21) : 6131 - 6134
  • [44] Protein kinase inhibitors as a therapeutic modality
    Levitzki, A
    ACCOUNTS OF CHEMICAL RESEARCH, 2003, 36 (06) : 462 - 469
  • [45] Recent Advances in Protein Kinase CK2, a Potential Therapeutic Target in Cancer
    V. B. Nipun
    K. A. Amin
    Russian Journal of Bioorganic Chemistry, 2022, 48 : 919 - 931
  • [46] Recent Advances in Protein Kinase CK2, a Potential Therapeutic Target in Cancer
    Nipun, V. B.
    Amin, K. A.
    RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2022, 48 (05) : 919 - 931
  • [47] Structural insights of oxindole based kinase inhibitors as anticancer agents: Recent advances
    Dhokne, Prajwal
    Sakla, Akash P.
    Shankaraiah, Nagula
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 216
  • [48] Recent Advances in Dual BRD4-Kinase Inhibitors Based on Polypharmacology
    Chen, Li
    Liu, Zhao-Peng
    Li, Xun
    CHEMMEDCHEM, 2022, 17 (06)
  • [49] Recent advances in the research and development of RAF kinase inhibitors
    Smith, Roger A.
    Dumas, Jacques
    Adnane, Lila
    Wilhelm, Scott A.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (11) : 1071 - 1089
  • [50] Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances
    Bryan, Marian C.
    Rajapaksa, Naomi S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (20) : 9030 - 9058